A complex interplay between Akt, TSC2 and the two mTOR complexes
- PMID: 19143635
- PMCID: PMC2778026
- DOI: 10.1042/BST0370217
A complex interplay between Akt, TSC2 and the two mTOR complexes
Abstract
Akt/PKB (protein kinase B) both regulates and is regulated by the TSC (tuberous sclerosis complex) 1-TSC2 complex. Downstream of PI3K (phosphoinositide 3-kinase), Akt phosphorylates TSC2 directly on multiple sites. Although the molecular mechanism is not well understood, these phosphorylation events relieve the inhibitory effects of the TSC1-TSC2 complex on Rheb and mTORC1 [mTOR (mammalian target of rapamycin) complex] 1, thereby activating mTORC1 in response to growth factors. Through negative-feedback mechanisms, mTORC1 activity inhibits growth factor stimulation of PI3K. This is particularly evident in cells and tumours lacking the TSC1-TSC2 complex, where Akt signalling is severely attenuated due, at least in part, to constitutive activation of mTORC1. An additional level of complexity in the relationship between Akt and the TSC1-TSC2 complex has recently been uncovered. The growth-factor-stimulated kinase activity of mTORC2 [also known as the mTOR-rictor (rapamycin-insensitive companion of mTOR) complex], which normally enhances Akt signalling by phosphorylating its hydrophobic motif (Ser(473)), was found to be defective in cells lacking the TSC1-TSC2 complex. This effect on mTORC2 can be separated from the inhibitory effects of the TSC1-TSC2 complex on Rheb and mTORC1. The present review discusses our current understanding of the increasingly complex functional interactions between Akt, the TSC1-TSC2 complex and mTOR, which are fundamentally important players in a large variety of human diseases.
Figures

Similar articles
-
The TSC1-TSC2 complex is required for proper activation of mTOR complex 2.Mol Cell Biol. 2008 Jun;28(12):4104-15. doi: 10.1128/MCB.00289-08. Epub 2008 Apr 14. Mol Cell Biol. 2008. PMID: 18411301 Free PMC article.
-
Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.Cancer Res. 2009 Aug 1;69(15):6107-14. doi: 10.1158/0008-5472.CAN-09-0975. Epub 2009 Jul 14. Cancer Res. 2009. PMID: 19602587 Free PMC article.
-
Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes.FEBS J. 2010 May;277(9):2180-91. doi: 10.1111/j.1742-4658.2010.07635.x. FEBS J. 2010. PMID: 20412061 Free PMC article.
-
Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.Cancer Biol Ther. 2003 Sep-Oct;2(5):471-6. doi: 10.4161/cbt.2.5.446. Cancer Biol Ther. 2003. PMID: 14614311 Review.
-
The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.Novartis Found Symp. 2004;262:148-54; discussion 154-9, 265-8. Novartis Found Symp. 2004. PMID: 15562827 Review.
Cited by
-
Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.Neoplasia. 2016 Jul;18(7):425-35. doi: 10.1016/j.neo.2016.06.001. Neoplasia. 2016. PMID: 27435925 Free PMC article.
-
mTOR Inhibitors at a Glance.Mol Cell Pharmacol. 2015;7(2):15-20. Mol Cell Pharmacol. 2015. PMID: 27134695 Free PMC article.
-
Neuroprotective effects of the anticancer drug NVP-BEZ235 (dactolisib) on amyloid-β 1-42 induced neurotoxicity and memory impairment.Sci Rep. 2016 May 4;6:25226. doi: 10.1038/srep25226. Sci Rep. 2016. PMID: 27142962 Free PMC article.
-
Jejunal proteins secreted by db/db mice or insulin-resistant humans impair the insulin signaling and determine insulin resistance.PLoS One. 2013;8(2):e56258. doi: 10.1371/journal.pone.0056258. Epub 2013 Feb 20. PLoS One. 2013. PMID: 23437106 Free PMC article.
-
Losartan affects glomerular AKT and mTOR phosphorylation in an experimental model of type 1 diabetic nephropathy.J Histochem Cytochem. 2013 Jun;61(6):433-43. doi: 10.1369/0022155413482925. Epub 2013 Mar 1. J Histochem Cytochem. 2013. PMID: 23456824 Free PMC article.
References
-
- Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7:606–619. - PubMed
-
- Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol. 1997;7:261–269. - PubMed
-
- Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–484. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous